These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 36777506)

  • 1. An overview of the correlation between IPI and prognosis in primary breast lymphoma.
    Feng K; Zhao S; Shang Q; Liu J; Yang C; Ren F; Wang X; Wang X
    Am J Cancer Res; 2023; 13(1):245-260. PubMed ID: 36777506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary diffuse large B-cell lymphoma of the breast: looking at pathogenesis, clinical issues and therapeutic options.
    Aviv A; Tadmor T; Polliack A
    Ann Oncol; 2013 Sep; 24(9):2236-44. PubMed ID: 23712546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of IPI in patients with primary breast lymphoma, a multicenter retrospective study.
    Feng K; Zhao S; Shang Q; Qiao G; Liu J; Yang C; Wei Y; Li Y; Ren F; Xuan L; Wang X; Wang X
    Cancer Cell Int; 2022 Nov; 22(1):357. PubMed ID: 36376836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of international prognostic indices in plasmablastic lymphoma: a comparative evaluation.
    Hertel N; Merz H; Bernd HW; Bernard V; Künstner A; Busch H; von Bubnoff N; Feller AC; Witte HM; Gebauer N
    J Cancer Res Clin Oncol; 2021 Oct; 147(10):3043-3050. PubMed ID: 33660007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modified number of extranodal involved sites as a prognosticator in R-CHOP-treated patients with disseminated diffuse large B-cell lymphoma.
    Yoo C; Kim S; Sohn BS; Kim JE; Yoon DH; Huh J; Lee DH; Kim SW; Lee JS; Suh C
    Korean J Intern Med; 2010 Sep; 25(3):301-8. PubMed ID: 20830228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standardized uptake value for (18)F-fluorodeoxyglucose is correlated with a high International Prognostic Index and the presence of extranodal involvement in patients with diffuse large B-cell lymphoma.
    Akkas BE; Vural GU
    Rev Esp Med Nucl Imagen Mol; 2014; 33(3):148-52. PubMed ID: 24094371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center.
    Huang H; Fan L; Fu D; Lin Q; Shen J
    Ann Palliat Med; 2020 Jul; 9(4):1442-1452. PubMed ID: 32648457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
    Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
    J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.
    Panizo C; Rodríguez AJ; Gutiérrez G; Díaz FJ; González-Barca E; de Oña R; Grande C; Sancho JM; García-Álvarez MF; Sánchez-González B; Peñalver FJ; Cannata J; Espeso M; Requena MJ; Gardella S; Durán S; González AP; Alfonso A; Caballero MD;
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):398-403. PubMed ID: 25843416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma.
    Hong J; Kim SJ; Chang MH; Kim JA; Kwak JY; Kim JS; Yoon DH; Lee WS; Do YR; Kang HJ; Eom HS; Park Y; Won JH; Mun YC; Kim HJ; Kwon JH; Kong JH; Oh SY; Lee S; Bae SH; Yang DH; Jun HJ; Lee HS; Yun HJ; Lee SI; Kim MK; Yi JH; Lee JH; Kim WS; Suh C
    Oncotarget; 2017 Nov; 8(54):92171-92182. PubMed ID: 29190906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic value of international prognostic index, revised international prognostic index, enhanced international prognostic index and Grupo Español de Linfomas/trasplante autólogo de médula ósea-international prognostic index for diffuse large B-cell lymphoma].
    Feng YX; Su LP
    Zhonghua Zhong Liu Za Zhi; 2020 Nov; 42(11):949-954. PubMed ID: 33256307
    [No Abstract]   [Full Text] [Related]  

  • 12. [The prognostic value of the international prognostic index, the national comprehensive cancer network IPI and the age-adjusted IPI in diffuse large B cell lymphoma].
    Song JL; Wei XL; Zhang YK; Hao XX; Huang WM; Wei Q; Wei YQ; Feng R
    Zhonghua Xue Ye Xue Za Zhi; 2018 Sep; 39(9):739-744. PubMed ID: 30369184
    [No Abstract]   [Full Text] [Related]  

  • 13. The Enhanced International Prognostic Index for Diffuse Large B-cell Lymphoma.
    Yang Y; Wang L; Ma Y; Han T; Huang M
    Am J Med Sci; 2017 May; 353(5):459-465. PubMed ID: 28502332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of the International prognostic index with β2-microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era.
    Chen H; Zhong Q; Zhou Y; Qin Y; Yang J; Liu P; He X; Zhou S; Zhang C; Gui L; Yang S; Zhou L; Shi Y
    BMC Cancer; 2022 May; 22(1):583. PubMed ID: 35624433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new extranodal scoring system based on the prognostically relevant extranodal sites in diffuse large B-cell lymphoma, not otherwise specified treated with chemoimmunotherapy.
    Hwang HS; Yoon DH; Suh C; Huh J
    Ann Hematol; 2016 Aug; 95(8):1249-58. PubMed ID: 27167532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients.
    Troppan KT; Melchardt T; Deutsch A; Schlick K; Stojakovic T; Bullock MD; Reitz D; Beham-Schmid C; Weiss L; Neureiter D; Wenzl K; Greil R; Neumeister P; Egle A; Pichler M
    Eur J Haematol; 2015 Dec; 95(6):538-44. PubMed ID: 25677782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk stratification model based on VEGF and International Prognostic Index accurately identifies low-risk diffuse large B-cell lymphoma patients in the rituximab era.
    Sang W; Zhou H; Qin Y; Shen Z; Yan D; Sun C; Song X; Ma Y; Tu D; Bian Z; Nie S; Jin Y; Xu L; Li Z; Xu K
    Int J Hematol; 2021 Aug; 114(2):189-198. PubMed ID: 33893987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early risk stratification for diffuse large B-cell lymphoma integrating interim Deauville score and International Prognostic Index.
    Yim SK; Yhim HY; Han YH; Jeon SY; Lee NR; Song EK; Jeong HJ; Kim HS; Kwak JY
    Ann Hematol; 2019 Dec; 98(12):2739-2748. PubMed ID: 31712879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Comparison of Clinical Prognostic Indices in Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with a Pegylated Liposomal Doxorubicin Combination Regimen in China.
    Gao H; Xu Y; Liu Y; Mi L; Wang X; Liu W; Zhu J; Song Y
    Cancer Manag Res; 2022; 14():2711-2721. PubMed ID: 36133738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma.
    Mian M; Marcheselli L; Rossi A; Visco C; Chiappella A; Volpetti S; Zaja F; Mondello P; Fiegl M; Billio A; Federico M; Luminari S; Rambaldi A; Cortelazzo S
    Ann Oncol; 2014 Dec; 25(12):2398-2404. PubMed ID: 25274614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.